Hostname: page-component-cd9895bd7-fscjk Total loading time: 0 Render date: 2024-12-22T21:43:59.519Z Has data issue: false hasContentIssue false
  • English
  • Français

Perceptions and knowledge of antipsychotics among mental health professionals and patients

Published online by Cambridge University Press:  02 January 2018

Lindah Cahling ,
Anders Berntsson ,
Gabriella Bröms  and
Lars Öhrmalm
Lindah Cahling
Affiliation:
PRIMA, Stockholm, Sweden
Anders Berntsson
Affiliation:
PRIMA, Stockholm, Sweden
Gabriella Bröms
Affiliation:
Karolinska Institutet, Stockholm, Sweden
Lars Öhrmalm*
Affiliation:
PRIMA, Stockholm, Sweden Karolinska Institutet, Stockholm, Sweden
*
lars.ohrmalm@prima.se
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Aims and method

To assess the patients' most influential concerns regarding long-acting injectable antipsychotics (LAIs) and mental health professionals' preconceptions about these concerns. For both groups, to assess the level of knowledge about LAIs. This cross-sectional study used semi-structured interviews of patients with schizophrenia or schizoaffective disorder (n = 164), nurses (n = 43) and physicians (n = 20).

Results

The mental health professionals overestimated many of the patients' fears of LAIs, and the expressed fears exceeded the actual experiences of patients already on LAIs. Acceptance to switch to LAIs was associated with shorter time from diagnosis. Nurses and patients disclosed limited knowledge of antipsychotics.

Clinical implications

Physicians and nurses should aim to identify the individual patient's concerns about LAIs in the discussion about choice of antipsychotic treatment early in the course of illness.

Type
Original Papers
Information
BJPsych Bulletin , Volume 41 , Issue 5 , October 2017 , pp. 254 - 259
Check for updates
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an open-access article published by the Royal College of Psychiatrists and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © 2017 The Authors

Footnotes

Declaration of interest

L.Ö. has received speaker honoraria from Otsuka Pharma Scandinavia AB and H. Lundbeck AB, and has accepted travel and hospitality payment from Otsuka Pharma Scandinavia AB.

References

1 Weiden, PJ. Understanding and addressing adherence issues in schizophrenia: from theory to practice. J Clin Psychiatry 2007; 68 (suppl 14): 14–9.Google Scholar
2 Weiden, PJ, Kozma, C, Grogg, A, Locklear, J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004; 55: 886–91.Google Scholar
3 Subotnik, KL, Nuechterlein, KH, Ventura, J, Gitlin, MJ, Marder, S, Mintz, J, et al. Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. Am J Psychiatry 2011; 168: 286–92.Google Scholar
4 Heres, S, Lambert, M, Vauth, R. Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics. Eur Psychiatry 2014; 29 (suppl 2): 1409–13.Google Scholar
5 Marcus, SC, Zummo, J, Pettit, AR, Stoddard, J, Doshi, JA. Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. J Manag Care Spec Pharm 2015; 21: 754–68.Google Scholar
6 Kirson, NY, Weiden, PJ, Yermakov, S, Huang, W, Samuelson, T, Offord, SJ, et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry 2013; 74: 568–75.Google Scholar
7 Dencker, SJ. The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective. J Clin Psychiatry 1984; 45: 22–7.Google ScholarPubMed
8 Gerlach, J. Depot neuroleptics in relapse prevention: advantages and disadvantages. Int Clin Psychopharmacol 1995; 9 (suppl 5): 17–20.Google Scholar
9 Agid, O, Foussias, G, Remington, G. Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention. Expert Opin Pharmacother 2010; 11: 2301–17.Google Scholar
10 Waddell, L, Taylor, M. Attitudes of patients and mental health staff to antipsychotic long-acting injections: systematic review. Br J Psychiatry 2009; suppl. 52: S43–50.Google Scholar
11 Patel, MX, De Zoysa, N, Bernadt, M, David, A. Depot and oral antipsychotics: patient preferences and attitudes are not the same thing. J Psychopharmacol 2009; 23: 789–96.Google Scholar
12 Weiden, PJ, Roma, RS, Velligan, Dl, Alphs, L, DiChiara, M, Davidson, B. The challenge of offering long-acting antipsychotic therapies: a preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophrenia. J Clin Psychiatry 2015; 76: 684–90.CrossRefGoogle ScholarPubMed
13 Beitinger, R, Kissling, W, Hamann, J. Trends and perspectives of shared decision-making in schizophrenia and related disorders. Curr Opin Psychiatry 2014; 27: 222–9.Google Scholar
14 Potkin, S, Bera, R, Zubek, D, Lau, G. Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia. BMC Psychiatry 2013; 13: 261.Google Scholar
15 Das, AK, Malik, A, Haddad, PM. A qualitative study of the attitudes of patients in an early intervention service towards antipsychotic long-acting injections. Ther Adv Psychopharmacol 2014; 4: 179–85.Google Scholar
16 Patel, MX, Haddad, PM, Chaudhry, IB, McLoughlin, S, Husain, N, David, AS. Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years. J Psychopharmacol 2010; 24: 1473–82.Google Scholar
17 James, BO, Omoaregba, JO, Okonoda, KM, Otefe, EU, Patel, MX. The knowledge and attitudes of psychiatrists towards antipsychotic long-acting injections in Nigeria. Ther Adv Psychopharmacol 2012; 2: 169–77.Google Scholar
18 Subotnik, KL, Casaus, LR, Ventura, J, Luo, JS, Helleman, GS, Gretchen-Doorly, D, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A randomized clinical trial. JAMA Psychiatry 2015; 72: 822–9.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.